Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.

This review summarizes current understanding of the molecular genetics of polycythemia vera and essential thrombocythemia, with an emphasis on JAK2V617F pathophysiology and effect on disease phenotype.
JAK2V617F exerts its effects on cell growth via janus kinase-signal transducer and activator of transcription (JAK-STAT) signalling and interactions with other molecules that normally negatively regulate signalling, such as suppressor of cell signalling 3. The role of mutant JAK2 on phenotype is discussed, as not all polycythemia vera patients appear to be homozygous for the JAK2V617F mutation. Other mutations in the JAK-STAT signalling cascade are reviewed, including JAK2 exon 12, myeloproliferative leukemia virus oncogene, LNK (also known as SH2B3) mutations, and epigenetic changes in ten-eleven-translocation-2 (TET2), additional sex combs like 1 (ASXL1), PcG enhancer of zeste homolog 2 (EZH2) and DNA methyltransferase 3A (DNMT3A). Mutations associated with disease progression such as isocitrate dehydrogenase (IDH) 1, IDH2, EZH2, serine/arginine-rich splicing factor 2 (SRSF2), p53, casitas B-lineage lymphoma (c-CBL), ikaros zinc fingers (IKZF), neurofibromin 1 (NF1) and runt-related transcription factor 1 (RUNX1) are described.
In this chapter, current knowledge regarding the role of the JAK2V617F mutation on the pathogenesis and disease phenotype of polycythemia vera and essential thrombocythemia are highlighted. Other more recently recognized mutations in the JAK-STAT signalling cascade, epigenetic changes and mutations associated with disease progression are summarized.
AuthorsGabriela Soriano, Mark Heaney
JournalCurrent opinion in hematology (Curr Opin Hematol) Vol. 20 Issue 2 Pg. 169-75 (Mar 2013) ISSN: 1531-7048 [Electronic] United States
PMID23298878 (Publication Type: Journal Article, Review)
Chemical References
  • Janus Kinase 2
  • Disease Progression
  • Humans
  • Janus Kinase 2 (genetics)
  • Mutation
  • Phenotype
  • Polycythemia Vera (genetics, therapy)
  • Thrombocythemia, Essential (genetics, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: